Histologic validation of auto-contoured dominant intraprostatic lesions on [

Dominant intraprostatic lesion Focal boosting Guided biopsy Magnetic resonance imaging Positron-emission tomography Prostate cancer

Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
11 2020
Historique:
received: 26 05 2020
revised: 22 07 2020
accepted: 14 08 2020
pubmed: 23 8 2020
medline: 15 4 2021
entrez: 23 8 2020
Statut: ppublish

Résumé

PSMA-PET To determine threshold and margin combinations that satisfy the following criteria: ≥95% sensitivity with max specificity and ≥95% specificity with max sensitivity. We registered pathologist-annotated whole-mount mid-gland prostatectomy histology sections cut in 4.4 mm intervals from 12 patients to pre-surgical PSMA-PET/MRI by mapping histology to ex-vivo imaging to in-vivo imaging. We generated PET-derived tumor volumes using boundaries defined by thresholded PET volumes from 1-100% of SUV Mean and standard deviation of sensitivity and specificity for cancer detection within the 2D oblique histologic planes that intersected with the 3D PET volume for each patient. A threshold of 67% SUV max with an 8.4 mm margin achieved a (mean ± std.) sensitivity of 95.0 ± 7.8% and specificity of 76.4 ± 14.7%. A threshold of 81% SUV max with a 5.1 mm margin achieved sensitivity of 65.1 ± 28.4% and specificity of 95.1 ± 5.2%. Preliminary evidence of thresholding and margin expansion of PSMA-PET images targeted at DILs validated with histopathology demonstrated excellent mean sensitivity and specificity in the setting of focal therapy/boosting and guided biopsy. These parameters can be used in a larger validation study supporting clinical translation.

Sections du résumé

BACKGROUND
PSMA-PET
OBJECTIVE
To determine threshold and margin combinations that satisfy the following criteria: ≥95% sensitivity with max specificity and ≥95% specificity with max sensitivity.
DESIGN, SETTING AND PARTICIPANTS
We registered pathologist-annotated whole-mount mid-gland prostatectomy histology sections cut in 4.4 mm intervals from 12 patients to pre-surgical PSMA-PET/MRI by mapping histology to ex-vivo imaging to in-vivo imaging. We generated PET-derived tumor volumes using boundaries defined by thresholded PET volumes from 1-100% of SUV
OUTCOME MEASUREMENTS
Mean and standard deviation of sensitivity and specificity for cancer detection within the 2D oblique histologic planes that intersected with the 3D PET volume for each patient.
RESULTS AND LIMITATIONS
A threshold of 67% SUV max with an 8.4 mm margin achieved a (mean ± std.) sensitivity of 95.0 ± 7.8% and specificity of 76.4 ± 14.7%. A threshold of 81% SUV max with a 5.1 mm margin achieved sensitivity of 65.1 ± 28.4% and specificity of 95.1 ± 5.2%.
CONCLUSIONS
Preliminary evidence of thresholding and margin expansion of PSMA-PET images targeted at DILs validated with histopathology demonstrated excellent mean sensitivity and specificity in the setting of focal therapy/boosting and guided biopsy. These parameters can be used in a larger validation study supporting clinical translation.

Identifiants

pubmed: 32827589
pii: S0167-8140(20)30726-X
doi: 10.1016/j.radonc.2020.08.008
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

34-41

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of interest The author(s) declare(s) that there is no conflict of interest. Funding sources were not involved in the conduct of the research and preparation of the article.

Auteurs

Ryan Alfano (R)

Baines Imaging Research Laboratory, London, Canada; London Health Sciences Centre, London, Canada; Western University Department of Medical Biophysics, London, Canada. Electronic address: ralfano2@uwo.ca.

Glenn S Bauman (GS)

London Health Sciences Centre, London, Canada; Western University Department of Medical Biophysics, London, Canada; Western University Department of Oncology, London, Canada. Electronic address: glenn.bauman@lhsc.on.ca.

Wei Liu (W)

London Health Sciences Centre, London, Canada; Western University Department of Oncology, London, Canada. Electronic address: wei.liu@lhsc.on.ca.

Jonathan D Thiessen (JD)

Western University Department of Medical Biophysics, London, Canada; St. Joseph's Health Centre, London, Canada; Western University Department of Medical Imaging, London, Canada. Electronic address: jonathan.thiessen@sjhc.london.on.ca.

Irina Rachinsky (I)

London Health Sciences Centre, London, Canada; Western University Department of Medical Imaging, London, Canada. Electronic address: irina.rachinsky@lhsc.on.ca.

William Pavlosky (W)

Western University Department of Medical Imaging, London, Canada. Electronic address: william.pavlosky@sjhc.london.on.ca.

John Butler (J)

St. Joseph's Health Centre, London, Canada. Electronic address: jbutler@lawsonimaging.ca.

Mena Gaed (M)

Western University Department of Pathology and Laboratory Medicine, London, Canada. Electronic address: mgaed@uwo.ca.

Madeleine Moussa (M)

London Health Sciences Centre, London, Canada; Western University Department of Pathology and Laboratory Medicine, London, Canada. Electronic address: madeleine.moussa@lhsc.on.ca.

Jose A Gomez (JA)

London Health Sciences Centre, London, Canada; Western University Department of Pathology and Laboratory Medicine, London, Canada. Electronic address: jose.gomezlemus@lhsc.on.ca.

Joseph L Chin (JL)

London Health Sciences Centre, London, Canada; Western University Department of Surgery, London, Canada; Western University Department of Oncology, London, Canada. Electronic address: joseph.chin@lhsc.on.ca.

Stephen Pautler (S)

St. Joseph's Health Centre, London, Canada; Western University Department of Oncology, London, Canada. Electronic address: stephen.pautler@sjhc.london.on.ca.

Aaron D Ward (AD)

Baines Imaging Research Laboratory, London, Canada; London Health Sciences Centre, London, Canada; Western University Department of Medical Biophysics, London, Canada; Western University Department of Oncology, London, Canada. Electronic address: award54@uwo.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH